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Abstract
Background: While the evidence of an association between the apolipoprotein E (APOE) *E4
allele and Alzheimer's disease is very strong, the effect of the *E4 allele on cognitive decline in the
general population is more equivocal. A cross-sectional study on the lifespan effects of the *E4
allele [1] failed to find any effect of the *E4 allele on cognitive performance at ages 20–24, 40–44
or 60–64 years.
Methods: In this four year follow-up study, we reexamine the effect of *E4 in the sample of 2,021
individuals, now aged 65–69 years.
Results: Performance on the Mini-Mental State Examination (MMSE) was significantly poorer for
*E4 homozygotes than heterozygotes or non-carriers. The effects of the *E4 genotype on cognitive
decline over four years were found on the MMSE and Symbol-Digit Modalities test but only when
controlling for risk factors such as head injury and education. Analyses were repeated with the
exclusion of participants diagnosed with a mild cognitive disorder, with little change.
Conclusion: It is possible that *E4 carriers become vulnerable to greater cognitive decline in the
presence of other risk factors at 65–69 years of age.
Background
There is clear evidence that the presence of the apolipo-
protein E4 allele (APOE *E4) is associated with increased
risk of Alzheimer's Disease (AD). Forty to forty-five per-
cent of individuals diagnosed with Alzheimer's type
dementia have at least one *E4  allele, compared with
approximately 15% of the American population [2,3].
Recent evidence also suggests that the risk of dementia is
increased synergistically in APOE *E4 carriers exposed to
additional health risks, such as head trauma, high alcohol
use [1,4,5], comorbid ischemic cerebrovascular disease
[6], or a previous stroke, [6,7].
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An important question to address is whether APOE *E4
carrier status is associated with more rapid cognitive
decline in the general population when those with either
dementia or preclinical dementia are excluded. To date,
evidence generally supports the finding that cognitive
decline is more rapid for *E4 carriers compared to non-
carriers in general population samples [8-10]. However, it
is not clear at what age the effects of APOE genotype
emerge. There have been relatively few prospective longi-
tudinal studies of midlife and young-old adult age groups.
One exception is a study by Greenwood and colleagues
[11] which reported that the *E4  allele was associated
with greater decline on a test of visual attention in a sam-
ple aged 50 years and older. Seventy four of the 94 partic-
ipants in the study had first degree relatives with AD,
resulting in a sample likely to be sensitive to early effects
of APOE, and also likely to include a number of individu-
als prodromal for dementia. A second study [12] repli-
cated the findings in a sample of 177 individuals (mean
age of 59 years), 80% of whom had a first degree relative
with AD. In the second study, the authors found effects on
memory for location and working memory, with the
effects being subtle and manifesting under conditions of
high processing demand. They concluded that the APOE
genotype "exerts effects on specific components of cogni-
tion in midlife" (p. 207). This conclusion concurs with
recent research reporting that the deposition of amyloid
beta in the brain appears to increase around this age
period. Amyloid beta protein (Aβ1–42) in the cerebrospi-
nal fluid decreases at about 60 years in both *E4 carriers
and non-carriers, a finding which implies that more amy-
loid is being deposited in the brain at this time, with the
rate being greater in *E4 carriers [13].
However, one of the largest studies of APOE including a
cohort of 60–64 year old individuals [1] failed to find an
effect of APOE on cognitive functioning. Six thousand five
hundred and sixty people aged 20–24, 40–44 and 60–64
years were studied using cross-sectional data. Age differ-
ences in cognitive functioning were observed among the
cohort groups, but no difference in cognitive performance
as a function of APOE *E4 status was observed in any of
the three age cohorts. We emphasized that these analyses
needed to be repeated as our samples aged.
The present study reports Wave 2 data from the 60–64
year old cohort (now aged 65–69 years) examined four
years later. Given that the sample may be at a critical age
for the onset of decline, we hypothesized that the rate of
cognitive decline over the four years from Wave 1 to Wave
2 would be greater for APOE *E4 carriers. Measures of
memory, speed and working memory were taken since
these are sensitive to cognitive aging and are early markers
of the development of dementia [14-16]. Given its epide-
miological significance and its widespread use as a screen-
ing tool for early cognitive decline, we also extended our
previous analysis to examine the effect of APOE *E4 on
the Mini-Mental State Examination, MMSE [17], a brief
screening test for dementia. Moreover, we predicted that
the effect of APOE *E4 was most likely to be observed in
interaction with other risk factors associated with AD. We
investigated head injury, a history of stroke or vascular
disease, high past or current alcohol consumption, low
educational status and low pre-morbid intelligence as risk
factors (see above). Additional support for the importance
of these risk factors comes from a review [18] confirming
the importance of APOE in the brain's response to injury,
and that carriers of the *E4 allele are more vulnerable to
the effects of head injury. With respect to education and
premorbid intelligence, the risk of more rapid memory
decline is greater in *E4 carriers with less than 10 years
education than those with more years [19]. The analyses
were repeated excluding individuals with any indication
of mild cognitive decline based on a clinical assessment.
Methods
Participants
The sample comes from the PATH Through Life Project
[20], a large community survey concerned with the health
and well-being of people who are 20–24, 40–44, and 60–
64 years of age. Participants were sampled from the elec-
toral rolls for the city of Canberra, Australia, and in the
neighboring town of Queanbeyan. Registration on the
electoral roll is compulsory for Australian citizens. Each
cohort is being followed up every 4 years over a total
period of 20 years. Results presented here concern the first
two waves of interviews with the 60 + cohort (conducted
in 2001–2002 and 2005–2006). Letters were sent to 4,832
persons 60–64 years of age inviting them to participate in
the PATH study. Non-participants included 34 people out
of the required age range, 182 had moved, 28 were dead,
209 could not be found, 1,827 refused or their English
was too poor to allow an interview, and 2,551 were inter-
viewed (58.3% of those found and in age range). The gen-
der breakdown of the sample was 1,319 men and 1,232
women.
At the second wave, 2,222 of the 60s cohort (87% follow
up rate) were interviewed. Of the 770 participants who
were not interviewed at the second wave, 234 refused or
were unable to be interviewed due to medical reasons, 25
could not be located and 70 died between the two waves.
Individuals of non-Caucasian background (n = 89) and
those who were not genotyped (n = 112) were excluded in
these analyses, leaving a total of 2,021 participants in the
final sample.
Survey procedure
Persons selected at random from the electoral roll were
sent a letter informing them of the survey and that anBMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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interviewer would contact them soon to see if they wanted
to participate. If a person agreed to participate, the inter-
viewer arranged to meet them at some convenient loca-
tion, usually the participant's home or the Centre for
Mental Health Research at the Australian National Uni-
versity. Most of the interview was self-completed on a
palmtop or laptop computer. However, testing by the
interviewer was required for the physical tests, for some of
the cognitive tests, and for a cheek swab from which DNA
could be extracted.
Ethics approval
Ethics approval was obtained from the Australian
National University's Human Research Ethics Committee.
Genotyping
Genomic DNA was extracted from cheek swabs using Qia-
gen DNA Blood kits (#51162; Qiagen Inc., Valencia, CA,
USA). To identify the six APOE genotypes comprising the
APOE *E2, *E3 and *E4 alleles, two single nucleotide pol-
ymorphisms (SNPs) were assayed using the TaqMan
method [Applied Biosystems Inc. (ABI), Foster City, CA,
USA]. SNP-specific primers and probes were designed by
ABI (TaqMan genotyping assays) and assays were per-
formed according to the manufacturer's instructions in 5
μl total volumes in 384-well plates. The polymorphisms
distinguish the *E2 allele from the *E3 and *E4 alleles at
amino acid position 158 (NCBI rs7412) and the *E4 allele
from the *E2 and *E3 alleles at amino acid position 112
(NCBI rs429358).
TaqMan real-time polymerase chain reaction assays (PCR)
were performed in an ABI 7900 HT machine, using a
cycling program of: 95°C for 10 min; 40 cycles of 95°C
for 15 sec and 60°C for 1 min. Six positive controls, one
for each genotype, and one negative control (water) were
included in each plate and were consistently called cor-
rectly. The genotypes of the six positive controls were con-
firmed by Cfo1  restriction fragment length analysis,
following PCR amplification of part of the APOE gene
[21].
Allelic frequencies were consistent with Hardy-Weinberg
expectations for the PATH 60+ age cohort for both Wave
1 (rs7412: χ2 = 1.631, df = 1, p > .20, n = 2,281; rs429358:
χ2 = 0.002, df = 1, p > .97, n = 2,281) and Wave 2 (rs7412:
χ2 = 2.140, df = 1, p > .14, n = 2,021; rs429358: χ2 = .646,
df = 1, p > .42, n = 2,021). For the purposes of this analysis,
participants were classified into three groups: *E4-/*E4-
(no *E4 alelle), *E4+/*E4- (heterozygous for *E4) and
*E4+/*E4+ (homozygous for *E4).
Predictor or control variables
Education
Educational attainment was measured using six questions
concerning the full spectrum of past and current primary
(elementary), secondary and tertiary educational attain-
ment. Responses to these questions were coded into a sin-
gle measure corresponding to the number of years of
education. For the purposes of the analyses, education
was then categorized into four groups: 0–12 years, 13
years (i.e., high school), 14–15 years, and 16 years or
more.
Head injury
Participants were classified as having head trauma if they
responded positively to a question asking whether they
had ever had a serious head injury that had caused them
to become unconscious, at either Wave 1 or Wave 2 [22].
Hazardous or harmful alcohol consumption
Past alcohol consumption was measured using two items
regarding the frequency and amount of alcohol consump-
tion at the time the participant was drinking at their high-
est level. Respondents with potentially hazardous or
harmful levels of drinking were identified as those who
averaged more than 14 standard drinks per week. Current
alcohol consumption was measured with the Alcohol Use
Disorders Identification Test (AUDIT) [23]. Respondents
who had a total AUDIT score of eight or higher were con-
sidered to be currently consuming harmful or hazardous
levels of alcohol [23].
Premorbid intelligence
Intelligence was estimated using lexical decision perform-
ance on the Spot-the-Word Test Version A (STW), which
asks participants to choose the real words from 60 pairs of
words and nonsense words [24].
Stroke history
History of stroke was ascertained using one question,
"Have you ever suffered a stroke, ministroke or TIA (Tran-
sient Ischemic Attack)?"
Current hypertension
Blood pressure was measured twice during the interview.
Readings for diastolic and for systolic pressure were aver-
aged for each interview. Hypertension was defined as hav-
ing a mean systolic blood pressure ≥ 140, a mean diastolic
blood pressure ≥ 90 at Wave 1 or as taking medication for
hypertension.
Cognitive tests
Speed
Mental speed was measured with the Symbol-Digit
Modalities Test, which asks the participant to substitute as
many digits for symbols as possible in 90 seconds [25].BMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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Reaction time (RT)
Reaction time (RT) was tested using a small box held with
both hands, with left and right buttons at the top to be
depressed by the index fingers [26]. There were four
blocks of 20 trials measuring simple reaction time (SRT),
followed by two blocks of 20 trials measuring choice reac-
tion time (CRT). Means were calculated after removing
outliers. This was done by first eliminating any values
under 100 ms or over 3,000 ms. Next, means and stand-
ard deviations were calculated for each individual for each
block, and values outside three standard deviations from
the individual's block mean were eliminated [26].
Memory
Immediate and delayed recall were assessed with the first
trial of the California Verbal Learning Test [27], which
involves recalling a list of 16 nouns. The interval between
immediate and delayed recall was occupied by a test of
grip strength.
Working memory
Working memory was assessed with the Digits Backwards
subtest of the Wechsler Memory Scale [28], which
presents participants with series of digits at the rate of one
per second and asks them to repeat the digits backwards.
General cognitive impairment
The 11 item Mini-Mental State Examination (MMSE) [17]
was administered primarily for screening purposes. How-
ever, the MMSE provides a reliable measure of mental sta-
tus, covering aspects of cognition (in particular,
orientation to time and place) that were not measured by
the other cognitive tests.
Cognitive change scores were calculated for each test by
subtracting Wave 1 scores from Wave 2 scores.
Clinical assessment
At each wave, participants who scored below a predeter-
mined cut-off on a screening battery were assessed for
clinical diagnoses. Participants from the full cohort were
selected for clinical assessment if they had any of the fol-
lowing: (1) a Mini-Mental State Examination (MMSE)
score ≤ 25; (2) a score below the 5th percentile score on
immediate or delayed recall of the California Verbal
Learning Test (immediate or delayed score of <4 and <2,
respectively), or (3) a score below the 5th percentile score
for Wave 1 on two or more of the following tests: Symbol-
Digit Modalities Test (<33), Purdue Pegboard with both
hands (Wave 1: <8; Wave 2 <7) or reaction time (third set
of 20 trials; Wave 1: > 310 ms; Wave 2: > 378 ms).
The clinical assessment in the PATH study has been
described previously [29]. It involved a Structured Clinical
Assessment for Dementia by one of two physicians which
included a neuropsychological assessment and the Clini-
cal Dementia Rating Scale. Where possible, an informant
interview was undertaken. Diagnoses were made by con-
sensus clinical judgment rather than by an algorithm
according to criteria for diagnoses of Mild Cognitive
Impairment [30], Age Associated Memory Impairment
[31], Age Associated Cognitive Decline [32], or Mild Neu-
rocognitive Disorder [33]. DSM-IV criteria were used to
assess dementia [33].
Analyses
A series of bivariate models were examined for the effect
of APOE genotype, other risk factors, and APOE genotype
by risk factor interactions on cognitive decline for each of
the seven cognitive tasks. Multivariate ANOVA models for
each cognitive change score were constructed, simultane-
ously including APOE genotype and any risk factors found
to predict cognitive decline in association with genotype.
Participants who did not complete a particular cognitive
test at either Wave 1 or Wave 2 were excluded from the
bivariate and multivariate analyses for that test. Sample
sizes for bivariate and multivariate models were n = 1953
for SDMT, n = 1961 for immediate recall, n = 1961 for
delayed recall, n = 1941 for digits backwards, n = 1953 for
MMSE, n = 1877 for simple RT, and n = 1860 for choice
RT. The reduced samples were due to a combination of
missing premorbid intelligence data (24 cases) and miss-
ing cognitive test data (range: 36–137 cases). Analyses
were repeated with the exclusion of those who were found
to have any of the clinical diagnoses at either measure-
ment point (n = 126). A significance level of .05 was used
for individual analyses.
Results
APOE Genotyping
The genotyping results for this sample have been
described previously in Jorm et al. [1]. In the 60+ sample
of 2,021 participants, there were 1473 (73%) *E4 non-
carriers, 510 heterozygous for *E4 (25%) and 38 (2%)
homozygous for *E4.
Demographics, risk factors and cognitive change as a 
function of APOE
Tables 1 and 2 show demographics, risk factors, cognitive
performance (Wave 2) and change scores (Wave 2 scores
minus Wave 1 scores) as a function of APOE genotype.
The p-values in Table 1 (predictor variables) are for chi-
square tests that were used to examine genotype differ-
ences for categorical variables. In Table 2 (cognitive tests),
the p-values are for F tests that were used for the continu-
ous cognitive variables. While there was a significant dif-
ference in the age distribution across APOE  genotype
categories, the difference was not significant when age was
treated as a continuous variable (F = 2.65, p = 0.071).
With the exception of RT, negative change scores indicateBMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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poorer performance at Wave 2. *E4 status did not increase
the risk of head injury, problem drinking, stroke or cur-
rent hypertension. There were no significant effects of
APOE genotype on gender, education or premorbid intel-
ligence.
As was expected, cognitive test scores declined signifi-
cantly over the 4 year period: SDMT (Wave 1 mean 50.67;
Wave 2 mean 49.62; t1953 = -8.14, p < .0001); Immediate
Recall (Wave 1 mean 7.31; Wave 2 mean 6.98; t1956 = -
7.00, p < .0001); Delayed Recall (Wave 1 mean 6.35; Wave
2 mean 6.16; t1956 = -3.83, p < .0001); Simple RT (Wave 1
mean 248 ms; Wave 2 mean 275 ms; t1870 = -19.37, p <
Table 1: Descriptive statistics for predictor variables by APOE genotype
*E4-/*E4- *E4+/*E4- *E4+/*E4+
(n = 1473) (n = 510) (n = 38)
n Freq (%) Freq (%) Freq (%) p
Age 60–62 1045 749 (71.7%) 282 (27.0%) 14 (1.3%) 0.040
63–64 976 724 (74.2%) 228 (23.4%) 24 (2.5%)
Gender Male 1049 764 (72.8%) 267 (25.5%) 18 (1.7%) 0.837
Female 972 709 (72.9%) 243 (25.0%) 20 (2.1%)
Education 0–12 years 632 452 (71.5%) 167 (26.4%) 13 (2.1%) 0.907
13 years 426 313 (73.5%) 107 (25.1%) 6 (1.4%)
14–15 years 207 156 (75.4%) 48 (23.2%) 3 (1.4%)
16+ years 756 552 (73.0%) 188 (24.9%) 16 (2.1%)
Head injury Yes 193 142 (73.6%) 47 (24.4%) 4 (2.1%) 0.941
No 1828 1331 (72.8%) 463 (25.3%) 34 (1.9%)
Problem drinking Yes 468 349 (74.6%) 110 (23.5%) 9 (1.9%) 0.617
No 1553 1124 (72.4%) 400 (25.8%) 29 (1.9%)
Premorbid intelligence Low 625 458 (73.3%) 159 (25.4%) 8 (1.3%) 0.599
(STW) Medium 718 514 (71.6%) 190 (26.5%) 14 (1.9%)
High 654 481 (73.5%) 158 (24.2%) 15 (2.3%)
Stroke or hypertension Yes 1118 813 (72.7%) 285 (25.5%) 20 (1.8%) 0.911
No 903 660 (73.1%) 225 (24.9%) 18 (2.0%)
Stroke history Yes 80 59 (73.8%) 19 (23.8%) 2 (2.5%) 0.882
No 1941 1414 (72.8%) 491 (25.3%) 36 (1.9%)
Current hypertension Yes 1212 882 (72.7%) 309 (25.5%) 21 (1.7%) 0.804
No 809 591 (73.1%) 201 (24.8%) 17 (2.1%)
Table 2: Descriptive statistics for cognitive tests by APOE genotype
*E4-/*E4- *E4+/*E4- *E4+/*E4+
(n = 1473) (n = 510) (n = 38)
n Mean (SD) Mean (SD) Mean (SD) p
Wave 2 SDMT 1984 49.55 (9.34) 49.71 (8.92) 48.00 (10.93) 0.547
Wave 2 immediate recall 1984 6.97 (2.22) 7.00 (2.09) 6.79 (2.74) 0.850
Wave 2 delayed recall 1984 6.18 (2.40) 6.12 (2.32) 5.89 (2.81) 0.704
Wave 2 digits backwards 1964 5.13 (2.21) 5.21 (2.22) 5.05 (1.80) 0.772
Wave 2 MMSE score 1974 29.24 (1.17) 29.25 (1.12) 28.71 (1.49) 0.021
Wave 2 simple RT (sec) 1925 0.28 (0.07) 0.28 (0.08) 0.26 (0.05) 0.659
Wave 2 choice RT (sec) 1919 0.33 (0.06) 0.33 (0.05) 0.32 (0.04) 0.902
Change in SDMT 1980 -0.99 (5.73) -1.07 (5.60) -1.63 (7.44) 0.781
Change in immediate recall 1984 -0.32 (2.07) -0.29 (2.06) -0.32 (2.49) 0.959
Change in delayed recall 1984 -0.17 (2.20) -0.22 (2.25) -0.21 (3.03) 0.907
Change in digits backwards 1962 0.09 (1.77) 0.30 (1.82) 0.27 (1.76) 0.075
Change in MMSE score 1971 -0.07 (1.16) 0.00 (1.17) -0.27 (1.43) 0.274
Change in simple RT (sec) 1897 0.03 (0.06) 0.03 (0.07) 0.02 (0.05) 0.892
Change in choice RT (sec) 1880 0.01 (0.04) 0.01 (0.04) 0.01 (0.04) 0.838BMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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.0001); Choice RT (Wave 1 mean 315 ms; Wave 2 mean
326 ms; t1853 = -11.99, p < .0001). MMSE deterioration
was marginally significant (Wave 1 mean 29.29; Wave 2
mean 29.24; t1946 = -1.94, p = .052). Digits Backward per-
formance improved (Wave 1 mean 5.00; Wave 2 mean
5.15; t1956 = -3.83, p < .0001). The observed effect sizes
(Cohen's d) of the changes in the cognitive variables were
.11 for SDMT, .14 for immediate recall, .07 for delayed
recall, .07 for digits backwards, .05 for MMSE, .44 for sim-
ple RT and .23 for choice RT. There was one effect of APOE
genotype on cognitive performance. At Wave 2, those
homozygous for *E4  performed more poorly on the
MMSE (F = 3.88, df = 2, p < .05). APOE genotype did not
significantly predict change in performance on any of the
cognitive tests.
Bivariate ANOVA models tested the interaction of APOE
genotype and the other risk factors on cognitive change.
Interaction effects of genotype on at least one cognitive
test were found with education (delayed recall and digits
backwards), head injury (SDMT) and premorbid intelli-
gence (MMSE). In addition, the main effect of APOE gen-
otype was significant for SDMT scores when adjusting for
head injury and for digits backwards scores when adjust-
ing for premorbid intelligence. No significant interaction
effects of APOE with gender, current or past hazardous
drinking, stroke or hypertension emerged. These five pre-
dictors were subsequently omitted from multivariate
models.
Multivariate models of the effects of genotype and risk 
factors on cognitive change scores
Table 3 shows the multivariate ANOVA models which
examined the effect of the significant risk factors (educa-
tion, head injury and intelligence) simultaneously. The
findings were similar to the bivariate analyses. When
accounting for the risk factors, APOE was found to be sig-
nificantly associated with performance on SDMT and dig-
its backwards. Interaction effects consistent with the
bivariate analyses were also present for genotype and edu-
cation (immediate and delayed recall), head injury
(SDMT and MMSE) and premorbid intelligence (MMSE).
All of the significant effect sizes were very small, with η2
ranging from 0.003 to 0.009. R2 for the models were also
very small, ranging from 0.001 to 0.01.
Figure 1 illustrates these interaction effects, with APOE
heterozygotes and homozygotes combined for simplicity.
The interaction between APOE genotype and education
was significant for both immediate and delayed recall
change scores (Figure 1, Panels A and B). *E4 carriers with
16 or more years of education showed less memory
decline than those with less education. However, among
non-carriers, those who were more highly educated (16
years) tended to show more decline on the recall tasks
than those with less education (0–15 years). There was a
greater decrease in MMSE scores among *E4 non-carriers
who experienced head injury (Figure 1, Panel D) than
among  *E4  carriers. Indeed, MMSE scores increased
among carriers who reported head injury. SDMT scores,
however, were greatly decreased among carriers who
reported head injury, while SDMT scores remained virtu-
ally unchanged for carriers without head injury and non-
carriers (Figure 1, Panel C). Premorbid intelligence had
opposite effects for *E4 carriers and non-carriers on the
change in their MMSE scores. Higher STW scores were
associated with an MMSE decrease among carriers, while
lower STW scores were associated with an MMSE decrease
among non-carriers. This finding may be associated with
ceiling effects on the MMSE (Figure 1, Panel E).
Table 3: Multivariate models of change scores
SDMT Immediate recall Delayed recall Digits Backwards MMSE Simple RT Choice RT
Fp F p F p F p FpFpFp
APOE Genotype 3.20 0.041 0.92 0.397 1.70 0.182 3.14 0.044 2.58 0.076 0.16 0.853 0.30 0.743
Education 2.09 0.099 0.86 0.461 0.32 0.812 1.61 0.185 2.49 0.059 0.08 0.971 0.51 0.674
Head injury 0.00 0.962 0.67 0.415 1.17 0.280 1.18 0.277 4.91 0.027 0.00 0.992 0.46 0.495
Premorbid intelligence 0.05 0.955 0.05 0.950 1.56 0.209 1.02 0.360 0.64 0.525 0.06 0.944 0.18 0.838
Genotype × Education 0.98 0.438 2.23 0.038 2.88 0.008 1.65 0.130 1.17 0.322 1.19 0.310 1.11 0.357
Genotype × Head injury 3.94 0.020 0.22 0.801 1.17 0.312 0.70 0.499 3.82 0.022 0.03 0.975 0.27 0.765
Genotype × Premorbid 
intelligence
0.47 0.757 1.04 0.388 2.32 0.054 1.07 0.370 2.71 0.029 2.04 0.087 0.35 0.842
Education × Head injury 1.72 0.160 1.04 0.375 0.12 0.951 1.26 0.285 2.68 0.045 0.55 0.650 0.78 0.504
Education × Premorbid 
intelligence
1.83 0.089 0.75 0.607 0.58 0.750 0.56 0.761 2.26 0.035 1.13 0.342 0.58 0.745
Head injury × Premorbid 
intelligence
0.25 0.778 1.18 0.307 0.06 0.941 0.97 0.379 0.13 0.879 0.83 0.435 1.38 0.253
Bold p-values represent p < .05;BMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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Charts of significant interaction effects Figure 1
Charts of significant interaction effects. Panel A: Changes in Delayed Recall as a function of APOE genotype and educa-
tion. Panel B: Changes in Immediate Recall as a function of APOE genotype and education. Panel C: Changes in SDMT as a func-
tion of APOE genotype and head injury. Panel D: Changes in MMSE as a function of APOE genotype and head injury. Panel E: 
Changes in MMSE as a function of APOE genotype and premorbid IQ. Error bars represent standard error of the mean.BMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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Analysis excluding those clinically diagnosed with mild 
cognitive disorders or dementia
The analyses were rerun excluding the participants with a
clinical diagnosis (n = 126). The proportion of partici-
pants with a diagnosis did not differ significantly across
genotypes (χ2 = 2.09, df = 2, p = .353). The main effect of
APOE genotype on MMSE at Wave 2 remained significant.
The multivariate model excluding participants with a clin-
ical diagnosis is shown in Table 4. Most of the significant
effects for the full sample were also found in this subanal-
ysis.
Discussion
The findings from the present analysis provide data on the
association of APOE *E4 genotype and decline in cogni-
tive performance over a four year period for individuals
aged 65–69 years at follow-up. In comparison to Wave 1
results from this study where no effects were observed, we
found that MMSE scores at Wave 2 were lower in *E4
homozygotes. Initial analyses showed no effect of geno-
type on cognitive change on any of the other cognitive
tests. However, in further analyses, the main effect of
APOE genotype was significant for SDMT when adjusting
for head injury, and digits backward when adjusting for
premorbid intelligence in further analyses. In addition,
other significant interaction effects emerged in these mul-
tivariate models. Most of these interactions were in the
predicted direction. Head injury was associated with
greater decline in those with the APOE genotype when
measured by the MMSE and fewer years of education were
associated with greater cognitive decline for those
homozygous or heterozygous for *E4 in association with
the additional risk factor.
As expected, given the age of our sample, the findings of
the present study are generally weaker than those from
other population studies examining the effects of geno-
type. These studies usually report relatively robust associ-
ations between *E4 and cognitive change. For example, a
study of 40 groups of USA-based Catholic clergy, aged 65
years or older (average age 76 years) reported that the *E4
allele was associated with faster decline on four cognitive
domains over 6 years, with the effect greatest for memory
[10]. Hofer et al. [8] reported faster rates of decline on
tests of memory and speeded tests for those with an *E4
allele in an representative sample followed for 7 years,
with the youngest aged 77 at follow-up. These findings
remained when those with mild cognitive impairment
were excluded. Similarly, Small, Basun and Backman [9]
reported faster rates of decline on tests of recognition
memory for those with *E4  compared to non-carriers
within a sample of participants without dementia aged
over 80 years. The weaker findings in our study are likely
to due to the younger age of the participants who were
mostly aged in their mid sixties.
The present study specifically sought to determine
whether the young old age group might be at a stage when
the effect of the APOE genotype 'kicked in'. Our findings
are consistent with the effects of APOE emerging at this
stage in those vulnerable as a result of the presence of an
additional risk factor. We found interactions of genotype
with education, intelligence and head injury, but not with
high alcohol use, stroke or cardiovascular risk. Earlier lon-
gitudinal work reported the effects of genotype emerging
in midlife in at risk individuals (those with a first degree
relative with AD) [11,12] and under research conditions
of high demand. However, given the few longitudinal
studies of mid to early old population samples, and some
inconsistent results from our own study, we believe that
the hypothesis that the effects of the genotype emerge at
this time requires further investigation.
Table 4: Multivariate models of change scores excluding mild cognitive disorders
SDMT Immediate recall Delayed recall Digits Backwards MMSE Simple RT Choice RT
Fp F p F p F p FpFpFp
APOE Genotype 2.56 0.077 0.48 0.617 1.95 0.142 2.09 0.124 3.55 0.029 0.09 0.916 0.20 0.819
Education 2.83 0.037 0.94 0.422 1.13 0.337 1.53 0.206 3.20 0.023 0.25 0.863 0.61 0.605
Head injury 0.05 0.830 0.00 0.969 0.03 0.866 0.88 0.349 5.88 0.015 0.06 0.808 0.53 0.466
Premorbid intelligence 0.02 0.976 0.13 0.880 1.97 0.140 1.39 0.250 0.21 0.814 0.05 0.950 0.06 0.946
Genotype × Education 1.08 0.370 2.41 0.025 3.59 0.002 1.58 0.150 1.16 0.323 1.15 0.331 1.01 0.415
Genotype × Head injury 3.24 0.039 0.35 0.702 0.85 0.426 0.46 0.633 4.09 0.017 0.03 0.972 0.20 0.823
Genotype × Premorbid 
intelligence
0.59 0.667 0.90 0.462 1.84 0.119 1.09 0.360 1.26 0.284 2.95 0.019 0.40 0.806
Education × Head injury 2.24 0.081 0.80 0.495 0.16 0.922 1.38 0.246 3.22 0.022 0.37 0.774 0.26 0.852
Education × Premorbid 
intelligence
1.80 0.095 0.76 0.602 0.65 0.686 0.72 0.634 0.86 0.520 1.11 0.353 0.59 0.739
Head injury × Premorbid 
intelligence
0.44 0.647 0.45 0.639 0.35 0.708 0.92 0.398 0.02 0.982 0.58 0.557 0.95 0.387
Bold p-values represent p < .05; Underlined p-values indicate tests which change from significant to non-significant or vice versa when participants 
with mild cognitive disorders are excludedBMC Geriatrics 2008, 8:14 http://www.biomedcentral.com/1471-2318/8/14
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Moreover, we consider that the positive findings we
reported in the study need to be considered in the context
of the number of non-significant findings on a range of
tests, the limitations in power and the short follow-up
period. As noted above, only one of seven cognitive tests
showed an effect on performance at Wave 2. Moreover,
the effects of the genotype on cognitive change were rela-
tively weak, only emerging when models included poten-
tial risk factors. The interaction effects were not always
consistent. Given these findings, it is important to con-
sider whether the observed associations may have
occurred by chance. Since a large number of potential
interactions and effects were evaluated, the chance of
obtaining a series of significant effects was high. However,
measured against this consideration is the knowledge
that, although the study is the largest of its type, the power
of the study is relatively modest for detecting interaction
effects between APOE *E4 and low prevalence risk factors
such as head injury, stroke and hazardous alcohol use [1].
The tests used were standard neuropsychological tests
which were not designed to measure performance under
conditions of high cognitive demand. Moreover, the time
period over which data are currently available is relatively
short. With little cognitive change to work with, the study
is (again) relatively underpowered. It is interesting to note
that if the research had been guided by an exploratory
rather than a hypothesis driven perspective, outcomes
might arguably be adjusted for multiple testing, perhaps
by imposing a p < 0.01 level of significance. If we had
taken this approach, only a few findings would have
emerged. However, those that meet this criterion are con-
sistent with the evidence that episodic memory tasks are
likely to be the ones most sensitive to APOE status (see for
example Nilsson et al. [34]).
Whether these significant effects came about because of
artifacts associated with psychometric properties of the
tests used must be considered. The effects of APOE were
present primarily for the MMSE. Reflecting its use as a
screen for dementia, this test features a number of items
that reflect orientation in time and location. It is assessing
impairment at a relatively high threshold. However, a
characteristic of the MMSE is its ceiling effect. This means
that it is easier to register decline, but hard to show
improvement. Models which recognize ceiling effects
(effectively considering the scores to be censored above)
involve very strong assumptions. We took the approach of
including only decliners – those showing a decline on the
MMSE – and repeating the analyses. The findings
remained unchanged. We also examined the proportion
of those decliners as a function of MMSE status, and
found similar results. One clear implication is that these
analyses warrant replication in four years when an addi-
tional wave of data will be available which tracks partici-
pants over a longer period into middle old age.
On balance, our interpretation of these findings is that
effects of APOE *E4 in association with risk factors may
begin to emerge after 60–65 years of age. The findings are
consistent with biochemical research [13], and with previ-
ous studies indicating that the effects of APOE  in the
young old may only emerge in interaction with other risk
factors and on tests sensitive to cognitive load [11,12]. We
predict that these initial findings will be replicated more
strongly at the next wave of the study.
Conclusion
Our earlier study provided evidence that APOE *E4 status
does not influence level of cognitive functioning for indi-
viduals aged 20–64 years. This suggested that cognitive
aging processes are influenced by other unknown or unin-
vestigated factors at this age range or that the effect of
APOE emerges at detectable magnitudes after 64 years of
age. Four years later, follow-up data suggest that APOE
*E4 is associated with poorer cognitive performance, as
measured by the MMSE, and may influence the rate of
cognitive decline in interaction with risk factors such as
previous head injury or low education. It is possible that
*E4 carriers appear to become vulnerable to greater cogni-
tive decline in the presence of other risk factors at this age.
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